{"organizations": [], "uuid": "ad37b07de59cdaffd79c695bdbd5f70310037826", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-exelixis-says-ipsen-received-valid/brief-exelixis-says-ipsen-received-validation-of-the-application-for-variation-to-the-cabometyx-idUSFWN1R90YY", "country": "US", "domain_rank": 408, "title": "BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-28T08:15:00.000+03:00", "replies_count": 0, "uuid": "ad37b07de59cdaffd79c695bdbd5f70310037826"}, "author": "", "url": "https://www.reuters.com/article/brief-exelixis-says-ipsen-received-valid/brief-exelixis-says-ipsen-received-validation-of-the-application-for-variation-to-the-cabometyx-idUSFWN1R90YY", "ord_in_thread": 0, "title": "BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx", "locations": [], "entities": {"persons": [{"name": "ipsen", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "exelixis", "sentiment": "none"}, {"name": "exelixis inc", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "cabometyx reuters staff", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 28, 2018 / 5:20 AM / Updated 4 minutes ago BRIEF-Exelixis Says Ipsen received validation of the application for variation to the Cabometyx Reuters Staff 1 Min Read March 28 (Reuters) - Exelixis Inc: * EXELIXIS’ PARTNER IPSEN ANNOUNCES EMA VALIDATION OF THE APPLICATION FOR A NEW INDICATION FOR CABOMETYX® (CABOZANTINIB) FOR PREVIOUSLY TREATED ADVANCED HEPATOCELLULAR CARCINOMA * ‍FILING IS BASED ON RESULTS OF GLOBAL PIVOTAL PHASE 3 CELESTIAL TRIAL, WHICH MET ITS PRIMARY ENDPOINT OF OVERALL SURVIVAL (OS)​ * ‍CABOZANTINIB PROVIDED A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN OS COMPARED WITH PLACEBO​ Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-03-28T08:15:00.000+03:00", "crawled": "2018-03-28T08:32:08.008+03:00", "highlightTitle": ""}